EUCTR2008-007482-23-FR进行中（未招募）1 期
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression
Dainippon Sumitomo Pharma America Inc.0 个研究点目标入组 340 人开始时间: 2009年11月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects 18 to 75 years of age, with bipolar I disorder, most recent episode depressed with or without rapid cycling disease course (= 4 episodes of mood disturbance but < 8 episodes in the previous 12 months) and without psychotic features (diagnosed by DSM-IV-TR criteria). The current episode of major depression associated with bipolar I disorder must be confirmed by the investigator and noted in the source records.
- •- Subjects must have a lifetime history of at least one bipolar manic or mixed manic episode. It is strongly recommended that a reliable informant (e.g., family member or caregiver) be available to confirm this history
- •-Subject’s current major depressive episode is = 4 weeks and less than 12 months in
- •- MADRS total score = 20 (at both screening and baseline visits)
- •- YMRS total score = 12 (at both screening and baseline visits)
- •- Lithium or divalproex levels must be within the protocol-defined therapeutic range (0.6-1.2 mEq/L for lithium or 50-125 ug/mL for divalproex) at screening and at least 28 days prior to the screening visit. The lithium or divalproex serum level obtained at least 28 days prior to screening must be documented in source records based on laboratory reports, chart records or communication from a health professional. All preparations of lithium, divalproex (including extended-release formulations), or valproic acid will be permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Diagnosis of an Axis I or Axis II disorder, other than bipolar I disorder, that is the primary
- •focus of treatment within 3 months prior to screening
- •- Subject scores = 4 on MADRS item number 10 (suicidal thoughts) at screening or baseline
- •- History of non-response to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
- •- Imminent risk of suicide or injury to self, others, or property
- •- Subject has been hospitalized for a manic or mixed episode within the 60 days prior to randomization
研究者
相似试验
进行中（未招募）
不适用
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I DepressioEUCTR2008-007482-23-DESunovion Pharmaceuticals Inc.340
进行中（未招募）
1 期
uradisone for the treatment of depression disorderEUCTR2012-004132-33-GBSunovion Pharmaceuticals Inc.209
进行中（未招募）
1 期
A 6-Week Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar DepressioBipolar depressionMedDRA version: 14.1Level: LLTClassification code 10004936Term: Bipolar depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2008-007482-23-CZSunovion Pharmaceuticals, Inc.340
已完成
3 期
A study to evaluate the efficacy of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-Response to Treatment with Lithium or Divalproex AloneCTRI/2011/06/001808Sunovion Pharmaceuticals Inc340
已完成
3 期
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depressioCTRI/2009/091/000647Dainippon Sumitomo Pharma America Inc